Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 2/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3178297 | 0.88 | PDK2 (0.41) | ALDH1A1PDK2BCHERAB9ANPC1 | |
| SCHEMBL5116460 | 0.88 | L3MBTL3 (0.48) | ALDH1A1HSD11B1BCHEOXTRL3MBTL3 | |
| SCHEMBL5111729 | 0.86 | NPC1 (0.49) | ALDH1A1PDK2RAB9ANPC1L3MBTL1 | |
| SCHEMBL27709208 | 0.85 | RAB9A (0.40) | ALDH1A1PDK2HSD11B1BCHERAB9A | |
| SCHEMBL5998189 | 0.83 | BCHE (0.45) | ALDH1A1BCHEL3MBTL1SMN1; SMN2 | |
| SCHEMBL5112751 | 0.82 | HRH3 (0.45) | ALDH1A1RAB9ANPC1OXTRL3MBTL1 | |
| SCHEMBL5118932 | 0.82 | NPC1 (0.43) | ALDH1A1PDK2HSD11B1RAB9ANPC1 | |
| SCHEMBL5118934 | 0.82 | NPC1 (0.43) | ALDH1A1PDK2HSD11B1RAB9ANPC1 | |
| SCHEMBL13394972 | 0.81 | RAB9A (0.38) | ALDH1A1PDK2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3178074 | 0.81 | RAB9A (0.47) | ALDH1A1PDK2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | claimed |
| CN-101128460-A | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-20 | — | — | CN | claimed |
| US-20060148823-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | claimed |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| CN-101128460-A | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-20 | — | — | CN | disclosed |
| EP-1846400-A2 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006074388-A2 | TRICYCLIC δ-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-13 | — | — | WO | disclosed |
| US-20060148823-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148823-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | ALDH1A1 1302/4885PDK2 4153/4885HSD11B1 603/4885 |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | ALDH1A1 1302/4885PDK2 4153/4885HSD11B1 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.